Emergent BioSolutions (EBS) Other Operating Expenses (2018 - 2025)

Emergent BioSolutions' Other Operating Expenses history runs 8 years deep, the most recent figure standing at -$12.2 million for Q1 2025.

• On a quarterly basis, Other Operating Expenses changed N/A year-over-year to -$12.2 million in Q1 2025; TTM through Dec 2025 was -$12.2 million, a 150.21% decrease from a year earlier, with the FY2025 full-year figure at -$12.2 million, down 150.21% from the prior year.
• Other Operating Expenses retreated to -$12.2 million in Q1 2025 per EBS's latest filing, from $64.3 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $305.2 million in Q4 2021 and bottomed at -$40.0 million in Q2 2024.
• The 5-year median for Other Operating Expenses is $114.2 million (2021), against an average of $120.0 million.
• Biggest YoY gain for Other Operating Expenses was 9285.71% in 2024; the steepest drop was 153.4% in 2024.
• Year by year, Other Operating Expenses stood at $305.2 million in 2021, then slumped by 44.33% to $169.9 million in 2022, then sank by 100.41% to -$700000.0 in 2023, then surged by 9285.71% to $64.3 million in 2024, then slumped by 118.97% to -$12.2 million in 2025.
• Per Business Quant, the three latest EBS Other Operating Expenses figures stand at -$12.2 million (Q1 2025), $64.3 million (Q3 2024), and -$40.0 million (Q2 2024).